Harrow to Present 15 Abstracts at AAOpt/AAO Highlighting Portfolio Data
Sep 30, 2026, 7:41 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Industry events with multiple Phase 3 and long-term safety data often trigger renewed interest in smaller-cap ophthalmology names if results are favorable. Historical examples include small-cap medtech/pharma stocks rallying on conference abstracts or positive Phase 3 readouts, though dismissing the risk that abstracts may not translate to full results or immediate revenue impact.
AI summary
What happened, with direct paths to the underlying reporting
Harrow plans 15 scientific abstracts at AAOpt and AAO in late 2026, spanning Phase 3 results, long-term safety, real-world evidence, and meta-analyses for VEVYE, VERKAZIA, FLAREX, and BYQLOVI. This broad data showcase could validate the portfolio and support clinician adoption, potentially lifting sentiment and valuation if results are favorable, though abstracts are not full trial reports.
Harrow to present 15 abstracts at AAOpt and AAO across portfolio.
13 AAOpt and 2 AAO presentations; includes Phase 3 results and 52-week safety data.
Pooled analyses, real-world evidence, and meta-analyses included across studies.
Conference dates: AAOpt Sept 30–Oct 3; AAO Oct 9–12, 2026.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
